Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandimmun Neoral versus tacrolimus in liver transplant recipients with recurrent hepatitis C
2009-010806-12Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2009
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cyclosporine, tacrolimus, pegylated interferon alpha and ribavirin in hepatitis C virus infection (2 arms), sponsored by Novartis. Primary endpoint: Sustained virologic response. Started May 2009; status: completed.
02
Drugs
cyclosporinetacrolimuspegylated interferon alpharibavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-010806-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010806-12.